TL;DR
This study reveals distinct salivary microbiome profiles in non-smoking female lung cancer patients, showing reduced microbial diversity and altered composition compared to healthy controls. Importantly, it establishes potential correlations between specific salivary bacteria and key immunocytochemistry markers used in lung cancer diagnostics, suggesting salivary microbiota could serve as a non-invasive biomarker.
What Problem Does This Paper Address?
Lung cancer remains a leading cause of cancer death globally. While smoking is a primary risk factor, a significant portion of lung cancers, particularly in women, occur in non-smokers. This distinct subgroup presents unique challenges for understanding disease etiology and developing diagnostic tools. Previous research has hinted at a link between oral bacteria and lung cancer risk, but this connection has not been thoroughly investigated in non-smoking women, nor has it been explored in relation to specific diagnostic markers. This paper aims to fill this gap by characterizing the salivary microbiome of non-smoking female lung cancer patients and exploring its association with immunocytochemistry markers commonly used in clinical diagnosis.
Methods
The researchers employed 16S rRNA gene amplicon sequencing to analyze the bacterial communities in saliva samples. This is a standard technique for profiling microbial communities. They compared the salivary microbiomes of 75 non-smoking female lung cancer patients with those of 172 matched healthy controls. To assess differences in microbial structure, they used Principal Coordinate Analysis (PCoA) with unweighted and weighted UniFrac distances, along with Analysis of Similarities (ANOSIM). For identifying specific bacterial taxa that differed between groups, they utilized Linear Discriminant Analysis Effect Size (LEfSe). To explore functional implications, they employed the PICRUSt program to infer functional pathways from the 16S rRNA data. Finally, they calculated Spearman's rank correlation coefficients to investigate the relationships between salivary microbiota composition and three key immunohistochemical markers: TTF-1, Napsin A, and CK7.
Datasets
The study utilized saliva samples collected from 75 newly diagnosed, untreated non-smoking female lung cancer patients and 172 matched healthy controls. These samples were collected from the Affiliated Central Hospital of Qingdao University. The 16S rRNA gene sequencing data has been uploaded to the NCBI SRA database under accession number SRP145042. No new benchmarks were introduced; rather, existing datasets were analyzed using established bioinformatics pipelines.
Key Insights and Ideas
- Salivary Microbiome as a Diagnostic Indicator: The study strongly suggests that changes in the salivary microbiome are not just a consequence of lung cancer but could potentially serve as an early indicator or biomarker.
- Distinct Microbial Signatures in Non-Smokers: The findings highlight that non-smoking female lung cancer patients have a unique salivary microbiome profile, distinct from healthy individuals, emphasizing the need to study this population separately from smokers.
- Microbiome-Biomarker Correlation: The novel finding of correlations between specific bacterial genera and immunocytochemistry markers (like CK7, Napsin A, and TTF-1) opens up new avenues for integrated diagnostic approaches.
- Functional Implications: The inferred functional analysis points towards pathways related to cancer, p53 signaling, apoptosis, and tuberculosis being enriched in lung cancer patients, suggesting a potential role of the microbiome in disease pathogenesis.
Key Results
- Reduced Diversity and Richness: Non-smoking female lung cancer patients exhibited significantly lower microbial diversity (Shannon index, P < 0.01) and richness (Ace index, P < 0.0001) in their saliva compared to healthy controls.
- Altered Microbiome Structure: The overall composition of the salivary microbiota differed significantly between the lung cancer and control groups (ANOSIM, r = 0.454, P < 0.001 for unweighted UniFrac; r = 0.113, P < 0.01 for weighted UniFrac).
- Differential Bacterial Abundance: The genera Sphingomonas (P < 0.05) and Blastomonas (P < 0.0001) were found to be relatively higher in lung cancer patients, while Acinetobacter (P < 0.001) and Streptococcus (P < 0.01) were more abundant in controls.
- Correlations with Immunocytochemistry Markers:
- CK7 showed a significant positive correlation with Enterobacteriaceae (r = 0.223, P < 0.05).
- Napsin A was positively associated with Blastomonas (r = 0.251, P < 0.05).
- TTF-1 exhibited a significant positive correlation with Enterobacteriaceae (r = 0.262, P < 0.05).
- Enriched Functional Pathways: Inferred metagenomic analysis indicated enrichment of pathways related to cancer, p53 signaling, apoptosis, and tuberculosis in non-smoking female lung cancer patients.
Limitations and Future Work
The authors acknowledge that this is a pilot study and further longitudinal studies are needed to confirm whether microbiome variations are causative factors for carcinogenesis or merely a consequence of the disease. They also suggest that while the study provides insights into the salivary microbiome's role in non-smoking female lung cancer, future research should aim to decipher the precise mechanisms of host-microbe interactions and their impact on immune responses and disease progression. Investigating the functional roles of specific bacteria and their bioactive molecules in the context of lung cancer pathogenesis is also a promising direction. The study's focus on a specific demographic (non-smoking females) is a strength but also implies that findings may not be generalizable to all lung cancer populations.
Summary updated